ReviewJournal of advanced research2017
Hepatitis C and kidney disease: A narrative review.
Review in Journal of advanced research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 78 citations in OpenAlex.
- Factors associated with chronic kidney disease among patients with hepatitis c infection attending Kigeme district hospital, Rwanda.Scientific reports · 2026Article
- Kidney dysfunction in adults living with HIV and HBV: a 10-year retrospective cohort study across seven Asia-Pacific countries.AIDS research and therapy · 2025Observational
- The Role of Viral Infections in Acute Kidney Injury and Mesenchymal Stem Cell-Based Therapy.Stem cell reviews and reports · 2025Review
- Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024Review
- Review
- Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals.Pathogens (Basel, Switzerland) · 2024Review
- Understanding the relationship between HCV infection and progression of kidney disease.Frontiers in microbiology · 2024Review
- IFN-γ, IL-17, IL-22American journal of clinical and experimental immunology · 2024Article
- Mitochondrial DNA copy number is associated with incident chronic kidney disease and proteinuria in the AIDS linked to the intravenous experience cohort.Scientific reports · 2023Article
- Focal Segmental Glomerulosclerosis Followed by Acute Hepatitis A Infection: Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection.Biology · 2022Review
- Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis.BMC infectious diseases · 2022Article
- Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.World journal of hepatology · 2022Review
- Propensity Score Modeling in Electronic Health Records with Time-to-Event Endpoints: Application to Kidney Transplantation.Journal of data science : JDS · 2022Article
- Article
- Urinary immunoglobulins in viral diagnosis: An overview.The Indian journal of medical research · 2022Review
- Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?Viruses · 2021Review
- Impact of acute kidney injury on survival in patients with chronic hepatitis C: a retrospective cohort study.BMC infectious diseases · 2021Article
- Predictive utility of fibrinogen in acute kidney injury in living donor liver transplantation: A propensity score-matching analysis.PloS one · 2021Article
- Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.Renal failure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis-C (HCV) infection can induce kidney injury, mostly due to formation of immune-complexes and cryoglobulins, and possibly to a direct cytopathic effect. It may cause acute kidney injury (AKI) as a part of systemic vasculitis, and augments the risk of AKI due to other etiologies. It is responsible for mesangiocapillary or membranous glomerulonephritis, and accelerates the progression of chronic kidney disease due to other causes. HCV infection increases cardiovascular and liver-related mortality in patients on regular dialysis. HCV-infected patients are at increased risk of acute post-transplant complications. Long-term graft survival is compromised by recurrent or de novo glomerulonephritis, or chronic transplant glomerulopathy. Patient survival is challenged by increased incidence of diabetes, sepsis, post-transplant lymphoproliferative disease, and liver failure. Effective and safe directly acting antiviral agents (DAAs) are currently available for treatment at different stages of kidney disease. However, the relative shortage of DAAs in countries where HCV is highly endemic imposes a need for treatment-prioritization, for which a scoring system is proposed in this review. It is concluded that the thoughtful use of DAAs, will result in a significant change in the epidemiology and clinical profiles of kidney disease, as well as improvement of dialysis and transplant outcomes, in endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.